NeuroStar ® ™S advances teen treatment during Mental Health Awareness Month



After receiving FDA breakthrough clearance, company focuses on stories of teens with major depression

MALVERN, Pa., May 01, 2024 (GLOBE NEWSWIRE) — Neuronetics, Inc. (Nasdaq: STIM) is a medical technology company focused on designing, developing and marketing products designed to improve the lives of neurologically healthy patients. Quality product disease, dedicated to supporting adolescents facing major depressive disorder (MDD). Following the recent U.S. Food and Drug Administration (FDA) approval of NeuroStar as a first-line add-on product for adolescents aged 15-21 years, NeuroStar™ S (transcranial magnetic stimulation) will uniquely have a significant impact on mental health conditions in young adults with MDD.

As the first ™S company to support an often underserved adolescent population, NeuroStar ™S is proud to highlight the resilience and perspective of patients receiving NeuroStar ™S treatment and the parents who support them along the way.

  • “I faced my own challenges as a teenager, and years of deep depression felt like an endless struggle. Discovering NeuroStar as a treatment option was like finding a new lifeline. “My first time in years “Chrissy, 15-year-old NeuroStar patient.
  • “As a parent, it's very frustrating to see that the only option available to Chrissy for her depression is an antidepressant with a black box warning that doesn't help her feel better. I was watching TV when I stumbled across NeuroStar ™S, it felt like a sign to do some research and it turned out to be the best decision I made for Chrissy's well-being.” Patricia, parent of a NeuroStar patient.
  • “I never thought I would feel so good again. Previously, my depression made everything so overwhelming and my academic experience and social life suffered. Four years ago I had my first NeuroStar Therapy, it changed everything for me “It changed the way I feel, my ability to focus in school, my grades totally reflect that, I feel more alive in my daily interactions with people, I really enjoy it Socializing and hanging out with friends again. “Shelly, 25-year-old NeuroStar patient.
3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads
.

Following FDA approval, NeuroStar is the first and only™S therapy available as a first-line add-on treatment for adolescents with depression, and is one of the most significant advancements in the treatment of this patient population in recent years. During Mental Health Awareness Month and beyond, NeuroStar encourages healthcare providers, caregivers and individuals affected by teen depression to explore NeuroStar's proven™S treatment solutions.For more information about NeuroStar™S therapy, please visit www.neurostar.com.

About teen depression
Teen depression is a complex and challenging mental health condition that affects young people during the critical period of adolescence.An estimated 4.3 million U.S. adolescents ages 15-21 are affected by MDDI. Depression in teenagers can disrupt key aspects of development, such as academic performance, relationships with peers and family members, and overall emotional well-being.

NeuroStar Advanced Therapy is designated as an adjunctive treatment for MDD in adolescent patients aged 15-21 years.

about Neurology (NASDAQ: )
Neuronetics, Inc. believes that mental health is just as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations through its NeuroStar advanced therapies for mental health. NeuroStar is a non-drug, non-invasive treatment that improves the quality of life for people with neurological diseases when traditional medical treatments fail. NeuroStar is indicated for the treatment of depressive episodes and the reduction of anxiety symptoms in adult patients with MDD who may be exhibiting comorbid anxiety symptoms and who have failed to obtain satisfactory improvement from prior antidepressant medication in the current episode . It is also FDA-approved as an adjunctive therapy for adults with OCD and adolescents with MDD aged 15-21 years. NeuroStar Advanced Therapy is the leading™S therapy for the treatment of adult MDD, with more than 6.1 million treatments provided. NeuroStar is supported by the largest clinical data set of any™S depression system, including the world's largest depression outcomes registry. Neuronetics is dedicated to changing lives by delivering exceptional treatments that produce extraordinary results.For safety and prescribing information, please visit www.neurostar.com.

3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads
.

Media contact information:
Evolution MKD
646.517.4220
NeuroStar@evolvemkd.com


I World Health Organization, Depression fact sheet. Date viewed: April 29, 2024.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *